EHDA Network-Pharmaceutical EHDA Technology: Developing QbD Facilitated, Continuous and Scaled Therapy Enabling Platforms
Lead Research Organisation:
De Montfort University
Abstract
Advances in fit for use manufacturing of biopharmaceutical drug delivery and pharmaceutical systems are now required to fit Quality by Design (QbD) models. These current regulations require excellence to be built into the preparation of emerging products (both material and process) thereby leading to product robustness and quality. In addition, industrial needs (economical and reproducible quality enhancement) are driving manufacturing towards continuous processes over batch type processes which also rely on QbD (for integrity and quality). EHDA technology is a robust process that has been utilised in various formats (e.g. electrospinning, electrospraying, bubbling and even 3D printing) and is favourable due to applicability with the development of stable nanomedicines and biopharmaceuticals, the emergence of this technology is clearly evident in the UK and on the global scale. Attempts in scaling up (for suitable pharmaceutical scale) and in tandem with continuous processes (including controlled manufacturing) have been very limited. There also, now, remains a huge void in the adaptation of sensible QbD (multi-variate) for the current methods developed and also those required by industry. While lab scale research continues with the ongoing development of such processes (e.g. nanomedicines, smart and controlled delivery), the transition to industry or the clinic will have to meet these regulations (and scales) for there to be a real impact, which is now, also, an important aspect of grass root research in the UK.
The EHDA network brings together specialists from academia and industry to advance this technology through several means. Firstly, initiating developments towards a real-viable scale for Pharmaceutical production. Secondly, to incorporate developments in lean manufacturing and legislation (e.g. continuous manufacturing, online diagnostics, QbD and adaptable scale). Thirdly, to marry optimised lean technologies with novel and emerging macromolecular therapies and actives. The network has a wide range of activities and initiatives which will lead to significant developments (and collaborations) in an area of increasing global interest (EHDA processes) - but currently only on a viable lab scale to date. This network will be the first of its kind and will serve as the central and pioneering hub in this remit.
The EHDA network brings together specialists from academia and industry to advance this technology through several means. Firstly, initiating developments towards a real-viable scale for Pharmaceutical production. Secondly, to incorporate developments in lean manufacturing and legislation (e.g. continuous manufacturing, online diagnostics, QbD and adaptable scale). Thirdly, to marry optimised lean technologies with novel and emerging macromolecular therapies and actives. The network has a wide range of activities and initiatives which will lead to significant developments (and collaborations) in an area of increasing global interest (EHDA processes) - but currently only on a viable lab scale to date. This network will be the first of its kind and will serve as the central and pioneering hub in this remit.
Planned Impact
This EHDA network will give rise to several initiatives (QbD, continuous processing and scale-up) which are meeting the needs of industrial manufacturing and much needed improved and novel therapeutic delivery. EHDA technologies already present desirable options in ambient condition preparation of pharmaceuticals, non-destructive preparation of biopharmaceutics (especially macromolecules) due to low energy processes, controlled encapsulation (layering, compartmentalisation and multi-coating thickness control on the nano and micron scales). In addition, improving solubility of emerging active chemicals (most of them poorly soluble) and offering morphological variations (fibres, particles, bubbles, capsules etc) while maintaining the aforementioned properties are also key factors for industry. Combining all these benefits will therefore significantly improve drug delivery science as well as reducing overall manufacturing costs, increasing efficiency, bringing new technologies to suitable production rates and meeting regulatory needs for impact case fruition (see letters of support from GSK, GEA Pharma, VolitionRX, Oncalytica and UCL-EMT).The impact of this work will also be crucial to pharmacists, pharmaceutical industries and scientists and the public in general, although other industries will also benefit where precision control on manufacturing is highly desirable.
Organisations
- De Montfort University (Lead Research Organisation)
- King Juan Carlos University (Collaboration)
- Zhejiang University (Collaboration)
- University of Portsmouth (Collaboration, Project Partner)
- UNIVERSITY OF SUNDERLAND (Collaboration)
- Aristotle University of Thessaloniki (Collaboration)
- Elvesys (Collaboration)
- Umetrics (Collaboration)
- University of Twente (Collaboration)
- Sympatec (Collaboration, Project Partner)
- University of Sussex (Collaboration)
- BlueFrog Design (Collaboration)
- Ashland (Collaboration)
- GenVolt Ltd (Collaboration, Project Partner)
- OncoLytika (Project Partner)
- University of Sunderland (Project Partner)
- University of Surrey (Project Partner)
- University of Sussex (Project Partner)
- University of Nottingham (Project Partner)
- GlaxoSmithKline (United Kingdom) (Project Partner)
- Imperial College London (Project Partner)
- Bluefrog Design (United Kingdom) (Project Partner)
- Loughborough University (Project Partner)
- University of Bath (Project Partner)
- Cardiff University (Project Partner)
- University of Sheffield (Project Partner)
- University College London (Project Partner)
- VolitionRX (Project Partner)
- Ashland Composite Polymers (Project Partner)
- University of Birmingham (Project Partner)
- Umetrics MKS AB (Project Partner)
- GEA Pharma Systems Ltd (Project Partner)
- Rotronic Measurment Solution (Project Partner)
Publications

Mehta P
(2018)
Broad Scale and Structure Fabrication of Healthcare Materials for Drug and Emerging Therapies via Electrohydrodynamic Techniques
in Advanced Therapeutics

Mehta P
(2017)
Pharmaceutical and biomaterial engineering via electrohydrodynamic atomization technologies.
in Drug discovery today

Nazari K
(2019)
Quality by Design Micro-Engineering Optimisation of NSAID-Loaded Electrospun Fibrous Patches.
in Pharmaceutics

Sayed E
(2018)
Electrosprayed mesoporous particles for improved aqueous solubility of a poorly water soluble anticancer agent: in vitro and ex vivo evaluation.
in Journal of controlled release : official journal of the Controlled Release Society
Description | DMU PhD Scholarships |
Amount | £60,000 (GBP) |
Organisation | De Montfort University |
Sector | Academic/University |
Country | United Kingdom |
Start | 09/2017 |
End | 09/2020 |
Description | Royal Society Industry Fellowship with BlueFrog Design |
Amount | £118,000 (GBP) |
Organisation | The Royal Society |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2016 |
End | 09/2020 |
Description | Collaboration with Elvesys- Paris |
Organisation | Elvesys |
Country | France |
Sector | Private |
PI Contribution | We have initiated a collaboration between De Montfort University and Elvesys in Paris. We have discussed a few EU projects and we are in the process of preparing for an ITN, Marie Curie bid. We visited the Elvesys centre in Paris and presented work and efforts of the EHDA Network |
Collaborator Contribution | They accommodated us in Paris. Gave us a tour of their facilities and also demonstrated what current projects they were interested in. |
Impact | none at present |
Start Year | 2017 |
Description | Collaboration with Prof Santiago Ruiz Gomez, Universidad Rey Juan Carlos (met at previous Conference) |
Organisation | King Juan Carlos University |
Country | Spain |
Sector | Academic/University |
PI Contribution | Visited the new University and had lunch with whole Department. Presented some of the EHDA Technologies we are developing. Discussed some emerging proposals or options. |
Collaborator Contribution | Tour of facilities. Presentation of their capabilities. Discussion of what materials they could provide to the collaboration. Recepton.. Agreed on some materials when needed at DMU. |
Impact | none yet |
Start Year | 2017 |
Description | Collaboration with University of Twente- Prof. Vancso |
Organisation | University of Twente |
Country | Netherlands |
Sector | Academic/University |
PI Contribution | Visited the Polymer Engineering Department and had tour of facilities. Discussed a previous ETN bid and re-evaluated with Prof Vancso. Proposed a new project for collaboration on EHDA technologies. Presented some of our recent work and capabilities |
Collaborator Contribution | Tour of facilities, Proposed selection of polymers and use of their facilities. Lunch reception with group members. Provided with further details of other links and contacts working with Prof. Vancso to include in further collaborations for EU bids |
Impact | none |
Start Year | 2017 |
Description | De Montfort University (Zeeshan Ahmad) and Ashland Specialist Ingredients |
Organisation | Ashland |
Department | Ashland Speciality Ingredients |
Country | United States |
Sector | Private |
PI Contribution | Application of QbD Models and EHDA Engineering Techniques |
Collaborator Contribution | New Polymeric Materials and expertise in polymer design for drug delivery |
Impact | This project is only underway |
Start Year | 2016 |
Description | De Montfort University and Blue Frog Design |
Organisation | BlueFrog Design |
Country | United Kingdom |
Sector | Private |
PI Contribution | We (Zeeshan Ahmad, De Montfort University) is contributing knowledge and concept ideas relating to EHDA Technology |
Collaborator Contribution | Blue Frog Design is contributing pharmaceutical engineering product know how and product design expertise |
Impact | This has only just started and is a funded project by the Royal Society There is also support from De Montfort University (fully funded studentship) |
Start Year | 2016 |
Description | De Montfort University and Genvolt |
Organisation | Genvolt Ltd |
Country | United Kingdom |
Sector | Private |
PI Contribution | Concept design for EHDA Technologies |
Collaborator Contribution | Development of new High Voltage supplies to meet the needs of the pharmaceutical Industry |
Impact | Initiated in 2016 |
Start Year | 2016 |
Description | De Montfort University and SympaTech |
Organisation | Sympatec |
Country | Germany |
Sector | Private |
PI Contribution | Utilising EHDA Technology to fit into the sizing process |
Collaborator Contribution | Development and advanced analysis of live sizing |
Impact | THis has just been initiated |
Start Year | 2017 |
Description | De Montfort University and Thessaloniki Pharmacy Greece |
Organisation | Aristotle University of Thessaloniki |
Country | Greece |
Sector | Academic/University |
PI Contribution | Advanced EHDA methods with optimised processing |
Collaborator Contribution | Technological advancement using ex-vivo barriers |
Impact | This collaboration is yielding data and we are seeking to publish two further articles from this. In addition there is an expectation to submit two EU grant bids. |
Start Year | 2016 |
Description | De Montfort University and Umetrics |
Organisation | Umetrics |
Country | Sweden |
Sector | Private |
PI Contribution | Expertise in EHDA Technology and parameter design |
Collaborator Contribution | Expertise in Quality by Design |
Impact | We have generated some data and this is going towards an article to be published with other partners involved. |
Start Year | 2015 |
Description | De Montfort University and University of Sunderland |
Organisation | University of Sunderland |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Development and application of advanced EHDA Technology |
Collaborator Contribution | Utilisation of rival technology for comparison (e.g. spray drying) |
Impact | There is an expectation to publish one research article from the data which is currently being generated |
Start Year | 2016 |
Description | De Montfort University and University of Sussex |
Organisation | University of Sussex |
Department | School of Biological Sciences |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Expertise in EHDA Technology |
Collaborator Contribution | Expertise in Spray Drying Technology |
Impact | We are exploring some initiatives at this stage with some exchange of information for a grant bid |
Start Year | 2017 |
Description | De Montfort University and Zhejiang University |
Organisation | Zhejiang University |
Country | China |
Sector | Academic/University |
PI Contribution | Expertise in EHDA with a focus on Pharmaceutical Engineering |
Collaborator Contribution | Expertise in EHDA with a focus on mechanical propsects |
Impact | Data has been generated through inkind support and collaborative research. There is an expectation to publish two articles.There is also a view to apply for funding where both partners can benefit. |
Start Year | 2016 |
Description | De Montfort University and the University of Portsmouth |
Organisation | University of Portsmouth |
Department | School of Earth & Environmental Sciences |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Development of emerging EHDA Techniques and Optimisation |
Collaborator Contribution | Biological assessment with some clinical aspects |
Impact | Data has been generated. There is an expectation to publish two papers. |
Start Year | 2015 |
Description | 2nd International Confernece on Pharmaceutical Technologies, with emphasis on EHDA methods |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Other audiences |
Results and Impact | Integrated EHDA Technologies into the mainstream through comparison and evaluation. Demonstration of UK capability in EHDA and other technologies. Networking. |
Year(s) Of Engagement Activity | 2017 |
Description | Academic-Industry experimental explorations |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Industry/Business |
Results and Impact | Getting industrial involvement is crucial to take EHDA Technologies further. Academics are interacting with industries at network meetings and then also trying to establish common ground between technologies and industrial interests for further advances. Industries are also understanding EHDA technologies a lot more and the benefits these can bring to current medication and as other therapies. Industries have important specialisms and have realised there is good reason to take such developments further. Industries supporting the research with inkind support. |
Year(s) Of Engagement Activity | 2016,2017 |
Description | Cross Institute Exploratory Research For Technology Enhancement |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Students (post-graduate) and/or academics undertake exploratory research based on network partner discussions. This includes visiting other laboratories on the network and also visiting some International research groups. There is also utilisation of technologies not accessible at their own location. Data generated will assist towards further work development and also possibly research manuscripts |
Year(s) Of Engagement Activity | 2015,2016,2017 |
Description | EPSRC EHDA Network International Conference |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | We organised this event and invited pioneers in the UK from several areas and also world-leading specialists who are Editors of top journals in the field and International prize winners. All those in the UK from students to established academics appreciated this. More importantly, very interesting discussions pursued with International speakers who were enlightened about the technology. Some of these speakers are seeking collaborative provision and have invited us to visit their laboratories- as expected. |
Year(s) Of Engagement Activity | 2016 |
Description | Engagement of early career researchers (ECRs) in leading events |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Postgraduate students |
Results and Impact | Involving early career researchers (ECR's) at networking events taking key roles (opening sessions and leading discussions) has provided them with recognition amongst their peers and other senior academics on the network. This also provides ECRs a chance to develop their skills and engage with experts in the field |
Year(s) Of Engagement Activity | 2016,2017 |
Description | Formal Sessio at the UK Premier Conference on Pharmaceutics- Dedicated session to EHDA Techologies. |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Other audiences |
Results and Impact | Invited to host a dedicated session on EHDA Technologies. Three talks by Network members. Integrated with Industry, academia and pharmacy practice. Explained the network and also the impact of the rapidly emerging technology. |
Year(s) Of Engagement Activity | 2017 |
Description | International Networking and Collaborative Provision |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | While the network covers key players in the UK (and we have also engaged pioneers in related fields in the UK too); this activity provides an opportunity to work with internationally leading researchers in drug delivery, pharmaceutics and technologies. We have had a positive response to date and this will further market our network and hopefully extend its outputs and acceptance. Furthermore, these collaborative fronts provide potential publication, funding and technological enchantment opportunities. |
Year(s) Of Engagement Activity | 2016,2017 |
Description | International dissemination |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Research around EHDA Technologies, sister (advanced merged) technologies and the efforts of the EHDA Network are being disseminated across UK, EU and Globally. This is being done through conferences, seminars and workshops. Conferences are wide reaching (pharmaceutical, materials, nanotechnologies, patient group driven, pharmacological) since our network has a broad coverage and expertise. We also have QbD (legislative), industrial and academic angles providing several points for contact. This provides collaborate provision through numerous themes. Network partners (and their students) are involved as we plan for long term impact for technological development, currently at the early stage |
Year(s) Of Engagement Activity | 2016,2017 |
Description | Network Special Issue in AAPSPharmSciTech Journal entailing EHDA Technology and General Emerging Pharm Tech Structure Theme |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Other audiences |
Results and Impact | A special issue was agreed by the Editor in Chief, Prof. Bill Williams, Texas and was part of the EPSRC EHDA Networks strategic plan. The thematic issue is co-edited by Prof. Z Ahmad and Prof. M Edirisinghe and was based around Nano and Microstructures which essentially covers EHDA technologies but also brings other technologies into the fold, especially those already accepted and well known. Ten articles have been published in the journal and the opening session acknowledges support. There is broad readership for the AAPSPharmSciTech Journal, which is part of the prestigious AAPS series. We also state that six articles have come from the EHDA Networks project partners which has increased our own capacity and outcomes. We also now begin to include EHDA Technologies in the same breath as existing technologies for researchers, industrialists and all others involved with emerging medicinal technologies. |
Year(s) Of Engagement Activity | 2016,2017 |
Description | Portsmouth workshop for ECRs on Pharmaceutucal Technologies including EHDA |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Postgraduate students |
Results and Impact | Educating ECRS on technological advances in relation to Pharmaceutics. Greater understanding of process linkages and benefits for each type. Networking for ECRS and between Academics. Broadening Industry participation and understanding of EHDA and other emerging technologies etc. |
Year(s) Of Engagement Activity | 2017 |
Description | Project Partner Meetings Between Multiple Specialists from Industry and Academia - Knowledge Advance and Technological Enhancement (including those from EU) |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Other audiences |
Results and Impact | Detailed Discussions between Academics and Industrialists on pre-designed work packets bringing specific expertise to the research group. In addition this provided further discussion and off-shoots for exploratory research and collaborative provision. Industry engaged fully with EHDA techniques showing keen interest |
Year(s) Of Engagement Activity | 2015,2016,2017 |
Description | Regular Steering Group Committee Meetings (De Montfort University) with the APS on Materials Science and Process Technologies and Manufacturing |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Policymakers/politicians |
Results and Impact | We have managed to persuade two of the APS focus groups to accept the benefits and emergence of EHDA technologies. We continue to work with the APS focus groups and we are now part of regular discussion at the bi-monthly meetings. We look forward to moving forward . |
Year(s) Of Engagement Activity | 2015,2016,2017 |
Description | Research and Technological Engagement with the Academy of Pharmaceutical Sciences UK -Recognition |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | The Academy of Pharmaceutical Sciences (APS) is the main organisation for Pharmaceutical Research in the UK. We have successfully persuaded them to include our efforts in EHDA to be represented alongside the well-established and emerging processes. We now have dedicated sessions at the APS and infact they were impressed to see the EHDA Network support part of the >15 posters at this event. They have also provided a provision for this on their web-pages for future events. |
Year(s) Of Engagement Activity | 2016,2017 |